Illumina (ILMN) Given Daily Media Sentiment Rating of 0.29
News headlines about Illumina (NASDAQ:ILMN) have trended positive recently, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Illumina earned a daily sentiment score of 0.29 on Accern’s scale. Accern also assigned media headlines about the life sciences company an impact score of 44.9373408986032 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the news stories that may have effected Accern Sentiment’s rankings:
- Azumio Introduces DNA-Based Insights into its Fitness Platform (finance.yahoo.com)
- Insider Selling: Illumina, Inc. (NASDAQ:ILMN) EVP Sells 1,671 Shares of Stock (americanbankingnews.com)
- Illumina, Inc. (ILMN) Hits 52-Week High – Modern Readers (modernreaders.com)
- Illumina Introduces a New Genomic Era (fool.com)
- The Illumina, Inc. (ILMN) Director Sells 20000 Shares of Stock (expressnewsline.com)
Shares of Illumina (NASDAQ:ILMN) opened at 199.23 on Thursday. Illumina has a 12 month low of $119.37 and a 12 month high of $199.82. The company’s 50 day moving average price is $176.74 and its 200 day moving average price is $172.43. The stock has a market capitalization of $29.09 billion, a PE ratio of 39.97 and a beta of 0.83.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.14. The firm had revenue of $662 million during the quarter, compared to analysts’ expectations of $642.38 million. Illumina had a return on equity of 19.69% and a net margin of 30.27%. Illumina’s revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.86 earnings per share. Equities analysts anticipate that Illumina will post $3.65 earnings per share for the current fiscal year.
A number of research analysts have issued reports on ILMN shares. Deutsche Bank AG set a $175.00 price target on Illumina and gave the company a “hold” rating in a report on Friday, July 28th. Canaccord Genuity raised Illumina from a “hold” rating to a “buy” rating and boosted their price target for the company from $170.00 to $215.00 in a report on Monday. Vetr downgraded Illumina from a “strong-buy” rating to a “buy” rating and set a $197.84 price target for the company. in a report on Wednesday, June 21st. Morgan Stanley reissued an “underweight” rating and issued a $122.00 price target (up from $115.00) on shares of Illumina in a report on Monday, July 10th. Finally, Barclays PLC reissued a “hold” rating and issued a $150.00 price target on shares of Illumina in a report on Wednesday, July 19th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $177.01.
In related news, Director Frances Arnold sold 825 shares of Illumina stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $174.77, for a total transaction of $144,185.25. Following the completion of the transaction, the director now directly owns 8,816 shares of the company’s stock, valued at $1,540,772.32. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Jay T. Flatley sold 15,000 shares of Illumina stock in a transaction on Tuesday, May 23rd. The stock was sold at an average price of $175.53, for a total value of $2,632,950.00. Following the transaction, the director now directly owns 534,176 shares of the company’s stock, valued at $93,763,913.28. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 134,010 shares of company stock valued at $23,946,015. 1.60% of the stock is currently owned by insiders.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.